While long-term survival rates for many cancers are on the rise, it’s been difficult to improve outcomes for people with pancreatic cancer. Experts predict that by 2020, pancreatic cancer will be the second most common cause of cancer deaths — behind only lung cancer — despite nearly a dozen other cancers being more common.
But thanks to a collaboration funded by the nonprofit organization Pancreatic Cancer Action Network called Precision Promise, people with pancreatic cancer may soon have access to more clinical trials — and, hopefully, better standard treatments as well. Read more . . .